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New tools to target and suppress Aedes populations are needed 
to protect people living in areas of risk for arboviral disease. The 
purpose of this document is to provide procedures and criteria for 
testing the efficacy of and evaluating vector traps for disease control. 
It includes the design of laboratory and small-scale field trials to 
assess the attraction and killing effects of vector traps and of large-
scale community trials to determine the efficacy of traps in reducing 
mosquito populations in the field and disease transmission. This 
document is intended to support product developers, programmes 
and testing institutions generate robust entomological evidence of the 
efficacy of vector traps for control and, for a first-in-class vector trap, 
evidence of the public health impact in reducing arboviral disease.
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ABBREVIATIONS AND ACRONYMS
ABV   Aedes-borne virus
AC50   concentration that attracts 50% of insects
AC90   concentration that attracts 90% of insects
AI    active ingredient
EI    emergence inhibition 
EI50   concentration that prevents emergence of 50% of adults 
EI90   concentration that prevents emergence of 90% of adults
FT    time to first take-off
IgG ELISA  immunoglobulin G enzyme-linked immunosorbent assay
IGR   insect growth regulator
LC50   concentration that kills 50% of insects
LC90   concentration that kills 90% of insects
NS1   nonstructural protein 1
PCR   polymerase chain reaction
VCAG   WHO Vector Control Advisory Group
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GLOSSARY
Active ingredient. The part of a product that has the primary action on the insect (e.g. 
pesticidal, behavioural, attractant).
Attractant. A biological or chemical (e.g. odorant) or other attractive element (e.g. 
visual, acoustic) that attracts mosquitos to a trap (also referred to as “bait”). 
Attractive oviposition trap. Trap designed to attract and kill gravid or ovipositing 
mosquitos.
Autodissemination. Picking up by adult mosquitos of an active ingredient from treated 
surfaces of a device or trap and transferring it to aquatic habitats in sufficient quantities to 
kill larvae or prevent pupae from emerging to adults. Also known as “horizontal transfer 
(of chemicals)” by mosquitoes (HTM), or “mechanical dissemination by mosquitoes 
(DSM)”.
Autodissemination devices. Devices designed to lure and contaminate mosquitos with 
a disseminating agent (e.g. an insect growth regulator) for its transfer to additional 
oviposition sites. 
Bait. See “attractant”.
Autodisseminant. See “disseminating agent”.
Discriminating concentration. Concentration of an insecticide that, during a standard 
length of exposure, discriminates the proportions of susceptible and resistant phenotypes 
in a mosquito population.
Disseminating agent (or “autodisseminant”). An active ingredient that is topically picked 
up by mosquitos from treated surfaces, retained and transferred to aquatic mosquito 
habitats.
Durability. In relation to vector traps, the physical integrity of a trap and its components 
over time.
Efficacy. With regards to traps, efficacy is the impact in lowering the mosquito population 
and/or disease incidence/prevalence in humans.
Efficacy trial. Study to estimate the effect of an intervention under the ideal conditions 
that can usually be achieved only in a trial, for example, by ensuring maximal coverage 
of the target population and adherence to the intervention.
Fast-acting insecticide. An insecticide that causes ≥ 80% mortality in susceptible target 
populations within 24 h of a 30-min exposure to the compound or its active ingredient.
First-in-class. Refers to the first trap for vector control with a novel entomological effect 
that is validated for public health value by the WHO Vector Control Advisory Group 
(VCAG) based on demonstration of entomological and epidemiological efficacy.
Incidence. The number of new cases of infection or disease arising in a population per 
unit time. 
vii
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Insecticide (see also “Pesticide”). Chemical product (natural or synthetic) that kills insects 
on contact or by fumigation. Ovicides kill eggs; larvicides kill larvae; pupacides kill 
pupae; and adulticides kill adult mosquitos. “Residual” insecticides remain active after 
application. Insecticides can be categorized as fast- or slow-acting.
Insect growth regulator. Compounds such as juvenile hormone analogues (juvenoids) 
and chitin synthesis inhibitors that prevent the emergence of viable adult insects from 
larval or pupal stages by disrupting adult development or transformation.
Large-cage studies. Trials conducted in large screened cages or rooms under controlled 
conditions of temperature and humidity. 
Next-in-class (see also “first in class”). Any new subsequent vector trap product 
having the same mode of action as the first-in-class trap product for which a VCAG 
recommendation has been made.
Pesticide. Any substance or mixture of chemical or biological agents intended for 
repelling, destroying or controlling any pest. The term includes microorganisms, insect 
and plant growth regulators, pesticide synergists and “safeners” that are integral to the 
satisfactory performance of the pesticide. The term “formulated pesticide” refers to any 
formulation containing a pesticide (1).
Semi-field trials. Trials conducted in screened enclosures in the natural ecosystem of a 
target disease vector. 
Seroincidence. Rate of occurrence of new infections (e.g. number of seroconversions) in 
the population over a period of time. 
Seroprevalence. Proportion of population with serological evidence of a previous 
infection.
Slow-acting insecticide. An insecticide that has its primary effect on mosquito mortality 
> 24 h after exposure. 
Trap. Structure or device unto which vectors enter and/or make contact with, which 
ultimately results in their their capture, death and/or sterilization. Traps may work by 
capturing and retaining mosquitos inside a physical structure (“capture–kill”) or by 
attracting and releasing mosquitos exposed to an insecticide or autodisseminant that 
will kill, sterilize or otherwise reduce vector populations after individuals leave the trap 
(“capture–release”).
Vector trap for disease control. A trap, as defined above, implemented with the aim 
of reducing vector density and vectorial capacity and ultimately decreased infection or 
disease in humans.
Vector trap for surveillance. A trap, as defined above, used to monitor the distribution, 
abundance and infection rates of vector populations.
viii
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1. INTRODUCTION
The geographical distribution of important human disease vectors is expanding, and new 
vectors and arthropod-borne diseases have emerged. Aedes aegypti is the primary vector 
for many arboviral diseases, including dengue fever, Zika, chikungunya and yellow fever, 
and is a growing global public health threat. New and improved tools and strategies 
are needed to suppress vector populations and reduce the transmission of Aedes-borne 
diseases. 
Traps are commonly used in vector surveillance to monitor the distribution, abundance and 
infection rates of vector populations. Several traps have been developed recently with the 
aim of vector control rather than surveillance; however, there are few trap-based control 
programmes, and evidence of a demonstrable effect in the field is required.  Traps could 
help to reduce disease transmission by lowering vector densities below a transmission 
threshold or selectively targeting the older female mosquitos responsible for transmission, 
shifting the age structure and reducing the abundance of infectious vectors. 
The purpose of this document is to provide procedures and criteria for testing the efficacy 
of and evaluating vector traps for disease control. It includes the design of laboratory and 
small-scale field trials to assess the attraction and killing effects of vector traps and of large-
scale community trials to determine the efficacy of traps in reducing mosquito populations in 
the field and disease transmission. This document focuses on traps for container-inhabiting 
Aedes spp. mosquitos (Ae. aegypti and Ae. albopictus). Other species of mosquitos, with 
different larval aquatic habitats (e.g. Anopheles, Culex, floodwater mosquitos), are not yet 
included; however, the general testing framework described could be extended to other 
traps after some modification, including those for other vector species.
Vector traps are devices into which vectors enter or otherwise make contact, which ultimately 
result in their death or sterilization. Traps target different stages of mosquito life (eggs, larvae, 
pupae or adults) or physiological stages (e.g. host-seeking or gravid females). The ability 
of traps to attract vectors may be a function of their physical design or chemical attractant; 
similarly, killing may be achieved through physical design with or without insecticides. In 
this document, the strategy of killing vectors in traps is referred to as “capture–kill”, whereby 
mosquitos that enter the trap are physically confined and exposed to a “fast-acting” chemical 
or biological insecticide (illustrated in Fig. 1). The trapping strategy whereby mosquitos 
enter the trap, come in contact with an insecticidal or sterilizing agent and then leave the 
trap are referred to as “capture–release” (2). In an autodissemination strategy, adult capture 
and exposure are amplified by transfer of the disseminating agent to wider aquatic habitats, 
where it kills larvae or prevent adults from emerging (3).
The WHO Vector Control Advisory Group (VCAG) has reviewed initial evidence on two 
broad classes of traps for control of Aedes vector populations: adulticidal oviposition traps, 
which target gravid female mosquitos (4, 5), and autodissemination devices, in which 
gravid adult females attracted to traps are contaminated with a “slow-kill” insecticide and 
a larvicide (IGR) for dissemination (6). Other traps, with new designs, attractants and 
insecticides, are being developed by manufacturers. The efficacy claims of new traps (on 
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the product label or elsewhere) must be validated, and the traps shown to adequately 
reduce Aedes populations and Aedes-borne disease before WHO can issue a policy 
recommendation for the broad public health use of traps for vector control. Once a policy 
recommendation has been developed, it is envisioned that vector trap products that are “next-
in-class”, thus having the same mode of action as a first-in-class product, will be assessed 
on entomological data only, and in most cases will not need to present epidemiological 
data for assessment. 
This document, prepared in response to recommendations of VCAG, is intended to provide 
support to product developers, programmes and testing institutions in generating robust 
entomological evidence of the efficacy of vector traps for control and, for a first-in-class vector 
trap, evidence of the public health impact in reducing arboviral disease. The guidelines 
will be the basis for WHO evaluation of new traps and assist countries in testing the 
effectiveness of traps for vector control locally. The guidelines may be modified once proof 
of principle is established (i.e. the public health value of vector traps for controlling vector-
borne disease) and as new designs, attractants, insecticides and test methods become 
available. 
With the rapid spread of Aedes-borne arboviral diseases, new tools for selective targeting 
and suppression of Aedes populations are required to protect people living in areas of 
risk. Traps and target-based strategies have been used successfully to reduce tsetse-borne 
trypanosomiasis (7). If vector traps are proven to be effective, they could supplement 
current methods and improve control of Aedes-borne arboviral diseases. Vector traps will 
be most effective when used as one component in a package of interventions, and when 
implemented by control programmes to ensure proper use, monitoring, servicing and 
deployment coverage to have the desired effects on mosquitos and disease. 
Vector Traps
Capture-kill Capture-release
Physical kill
Fast-acting 
insecticide
Slow-acting 
insecticide 
and/or 
autodisseminant
Fig. 1. Vector traps covered in this document
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2. GENERAL CONSIDERATIONS FOR TESTING  
As biological tests are subject to variation, they should be conducted under the close 
supervision of personnel who are familiar with methods for testing vector control products 
and compounds, using sound scientific and experimental procedures. Use of standard 
operating procedures for testing and for data processing, management and validation 
is advisable, and training of laboratory and field personnel should be documented. 
WHO recommends testing according to good laboratory practice as defined by the 
Organisation for Economic Co-operation and Development (2). When possible, testing 
institutions certified as adhering to good laboratory practice should be used for testing 
vector traps for WHO evaluation and prequalification listing.1
These guidelines are designed for evaluation of whole traps and associated attractants 
and/or insecticides that have already been assessed for risk and hazard. It is important 
that, before testing, investigators review material safety data sheets, draft product labels 
and certificates of compliance with manufacturing specifications and any supporting 
data. Independent physical and chemical assessment for compliance with the 
manufacturer’s product specifications may be required. 
Data should be collected and reported in such a way as to allow comparisons among 
numerous evaluation sites. For field trials, the number of replicates should be based 
on sample size estimates to ensure that a statistical evaluation has enough power to 
demonstrate efficacy. At a minimum, the data to be reported are a measure of centrality 
(e.g. mean, median or proportion), sample size and a measure of variability (e.g. 
standard error, 95% confidence interval or interquartile range). 
Evaluations of vector traps should be conducted in accordance with applicable national 
ethical regulations, including experimental use permits for field trials. Any adverse effects 
on humans or potential non-target effects during relevant phases of testing should be 
recorded and reported. 
The criteria and methods described in these guidelines will be updated by WHO as new 
traps, assessment methods and efficacy data become available. The test requirements 
for vector traps are summarized in Table 1.  
1. The WHO prequalification team for vector control products, also known as PQT-VC, should be 
consulted for advice on risk assessments, specifications and prequalification requirements (http://
www.who.int/pq-vector-control/en/, accessed September 2018).
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Table 1. Types of studies for testing the efficacy of vector traps 
Testing stage Outcome or  
end-point
Applicable to Indicator
Laboratory studies Intrinsic activities of 
new AIs
New AIs only LC50 and LC90 (both adulticides and larvicides), IE50 and IE90 
(IGR), AC50 and AC90 (attractants) 
Excito-repellency New AIs only FT50 and FT90
Transfer of 
autodisseminant
New AI for auto-
dissemination only
LC50 or LC90 or EI of susceptible larvae exposed via transfer 
of the autodisseminant
Discriminating 
concentration 
New AIs only Discriminating concentration of AI
Cross-resistance New AIs only Cross-resistance to other insecticides in unrelated insecticide 
classes
Bioefficacy of 
formulation
All traps, AI 
formulations 
Percentage efficacy and duration efficacy is maintained to 
product claims
Contained and 
small-scale field 
trials
Trap efficacy All traps: CK, CR Immediate and delayed mortality (adults and/or larvae) 
or EI
All traps: CK, CR Trap oviposition rates (# eggs per trap)
CR traps only Adult EI (%) from secondary containersa
Effective trap 
duration
All traps: CK, CR Number of days or weeks during which efficacy end-points 
meet product claims
Effective trap 
density
All traps: CK, CR Optimal number of traps per unit area
Field trials for 
entomological end-
points
Entomological 
efficacy in the field
All traps: CK, CR Significant difference in mosquito population density 
between treated and control areas
All traps: CK, CR Significant decrease in proportion of older female (parous) 
mosquitos
Durability and 
attrition
All traps: CK, CR Day on which efficacy indicators are not different from no 
trap
Non-target effects All traps: CK, CR Observed negative effects on non-target organisms
Community trials 
for epidemiological 
end-points 
Public health 
efficacy
First-in-class only Target disease incidence or transmission
Entomological outcomes (above)
Community perceptions and acceptance of the intervention
Adverse events per person exposed to traps and/or control
AC, attractant concentration; AI, active ingredient; CK, capture–kill; CR, capture–release; EI, emergence inhibition; FT, time to first 
take-off; LC, lethal concentration; 
a This step is required only when traps include an autodissemination component.
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3. LABORATORY STUDIES 
Laboratory studies include tests on new active ingredients (AIs) and formulated products 
only. The efficacy of whole traps is studied in contained and small-scale field trials 
(section 4) and in large-scale field testing (section 5). 
For vector traps, laboratory studies determine the intrinsic biological activity of new active 
ingredient(s) used in the traps, discriminating concentration and any cross-resistance with 
known insecticide resistance mechanisms. Laboratory studies also include determination 
of the efficacy and residual activity of formulated trap component products
The following objectives are relevant only for new molecules (AIs) for which evidence in 
the target vector has not been previously generated:  
• to establish dose–response relations and determine the lethal concentration (LC) 
of fast- and slow-acting insecticides for 50% (LC50) and 90% (LC90) mortality or 
emergence inhibition (EI) of susceptible larval and adult mosquitos;
• to establish dose–response relations and determine the attractant concentration 
(AC) of a bait active for 50% (AC50) and 90% (AC90) attraction of mosquitos 
towards a chemical stimulus;
• to determine the “time to first take-off” (FT) for 50% (FT50) and 90% (FT90) of 
mosquitos after exposure to the insecticide-treated substrate;
• to establish the dose–response relation of an AI for autodissemination on adult 
mosquitos to achieve LC50 and LC90 of susceptible mosquito larvae that are 
exposed by transfer of the autodisseminant from the adult to the larval habitat; 
• to assess cross-resistance of the insecticide against unrelated classes of 
insecticide; and 
• to establish discriminating concentrations for monitoring susceptibility.1
Additionally, for formulated trap component products, the objective is to determine the 
efficacy and residual activity of a formulated AI or other agent (e.g. adulticide-treated 
netting, larvicide product).
3.1  GENERAL CONSIDERATIONS FOR TESTING
In order to standardize test outcomes at the laboratory stage as far as possible, laboratory 
tests should be conducted on well-characterized susceptible laboratory strains of Ae. 
aegypti or Ae. albopictus. The mosquito species and colony strain used in the test must 
be reported. If tests are done with other species of vectors (e.g. Anopheles or Culex), 
well-characterized laboratory strains should also be used and the species and colony 
strain reported.
1. Discriminating concentrations are already known for many insecticides. They should be determined 
only when they are not yet known for the target vector species.
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Standardized mosquito rearing and testing conditions are essential to ensure the reliability 
and reproducibility of data. Existing institutional standard operating procedures (8–11) 
should be followed or adapted as necessary. Mosquitos are usually reared at 27 °C 
± 2 °C, at 80% ± 10% relative humidity and a 12:12 h light:dark photoperiod. Test 
mosquitos are maintained on sugar meals (e.g. 10% sucrose) and can be non-blood-
fed or blood-fed, depending on the mosquito physiological stage that is targeted by 
the trap. Most ovitrap AIs and components should be evaluated in 6–8-day-old gravid 
female mosquitos that took their first blood meal 2–4 days before the experiments. 
Host-seeking mosquitos are usually 3–5 day-old non-blood-fed females that have been 
sugar-starved for 24 h. Institutional protocols should be followed for rearing mosquitos 
to the desired physiological stage.
When possible, each test should include a negative control, with no insecticide or 
attractant, and a positive control, such as a reference attractant or insecticide for which 
there are data.
Equipment must be thoroughly cleaned between tests to ensure that residual material 
does not bias the test results.
3.2 ASSESSMENT OF INTRINSIC ACTIVITY 
Intrinsic activities are assessed for novel AIs only when the biological activity against 
mosquitoes has not already been shown. The tests are not relevant for non-chemical 
components that are not produced to a manufacturing standard (e.g. hay infusion 
as attractant) or for formulated products (e.g. treated netting, water-soluble larvicide 
granules) used in traps. The relevant testing methods are summarized below.1 
3.2.1 ADULTICIDES
To evaluate the intrinsic biological activity of a mosquito adulticide, laboratory-reared 
adult female mosquitos are exposed to a range of concentrations of the AI applied 
topically, and mortality is recorded. Topical application is used to differentiate the 
toxicity from confounding effects on insect behaviour. Details of testing procedures for 
intrinsic activity can be found in the WHO guidelines for testing mosquito adulticides 
for indoor residual spraying and treatment of mosquito nets (12); refer to section 2.1 of 
referenced guidelines and relevant SOPs.   The bioassay procedures are the same for 
slow-acting as for fast-acting adulticides, except that, for the latter, mortality is monitored 
every 24 h until the full effect has been achieved. 
3.2.2 LARVICIDES
The objective is to measure the inherent biopotency of a mosquito larvicide against 
the target species. Laboratory-reared mosquito larvae are exposed to a range of 
1. For each referenced WHO guidelines, the most recent version should be followed and, where 
available, the relevant WHO standard operating procedures.
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concentrations, and mortality or EI is recorded. Details of testing procedures and larval 
bioassays can be found in the WHO guidelines for testing mosquito larvicides (13); 
refer to section 2.1 of referenced guidelines and relevant SOPs. 
3.2.3 ATTRACTANTS
The intrinsic activity of attractant AIs (including dose-response) may be a critical 
component of trap efficacy. Evidence should be provided demonstrating the basic 
ability of a new synthetic active ingredient to attract mosquitos. Laboratory-reared adult 
mosquitos are exposed to at least five concentrations within the activity range defined by 
the manufacturer or published literature. Attraction is measured in a Y-tube olfactometer 
in the absence and presence of the candidate compound. Tests are done on host-
seeking or gravid mosquitos, depending on the physiological state targeted. Details on 
testing procedures can be found in WHO guidelines for testing spatial repellents (25); 
refer to section 2.1 of referenced guidelines and any relevant SOPs. These methods 
may need further development and validation as new attractant molecules are brought 
forward for use in vector control.
3.2.4 ASSESSMENT OF EXCITO-REPELLENT ACTIVITY
The repellent and irritant effects of an insecticide can modify the tarsal contact time 
with a treated substrate, which may reduce the lethal effect of an adulticide or reduce 
the probability that adult mosquitos will be contaminated and subsequently transfer the 
autodissemination agent. WHO cone assays may be used to assess the time between 
first landing and take-off for individual mosquitos exposed to technical-grade insecticide 
on filter paper and relevant formulations. Further details and test procedures are 
described in reference (12); refer to section 2.3 of referenced guidelines and relevant 
SOPs.
3.2.5 AUTODISSEMINATION
For AIs and formulations for autodissemination, modified bottle bioassays can provide 
information on the transfer of an AI to the adult mosquito (see supplemental materials). 
In brief, adult females are exposed to concentrations of the autodisseminant in glass 
bottles and then placed in screened cages with bioassay containers holding susceptible 
immature mosquitos. Larval mortality or EI is measured to establish the dose–response 
relation for 50% and 90% mortality in susceptible larvae. 
Additional development and validation of bioassays may be required for different 
autodissemination agents and to evaluate other effects on mosquito physiology, such as 
chemosterilization. Suggested efficacy indicators for chemosterilization include total and 
mean number of eggs laid, hatchability and oviposition inhibition.1  
1. The 2018 WHO guidelines for laboratory and field-testing of long-lasting insecticidal nets currently 
under development and related SOPs should be consulted for details on assessment of reproductive 
output.
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3.3 DISCRIMINATING CONCENTRATION AND CROSS-RESISTANCE  
Discriminating concentrations of all new insecticides for vector control are required for 
monitoring insecticide resistance in the vectors and to assess whether an intervention will 
be effective against local mosquitos (14). Test procedures should accord with WHO 
standard procedures for establishing discriminating concentrations (15).
New AIs submitted for evaluation should also be tested to determine whether there is 
cross-resistance with known resistance mechanisms. New compounds can first be tested 
against multiresistant strains of mosquitos and then against insect strains carrying one or 
more resistance mechanisms, as per WHO guidance (12, 15).
 
3.4 BIOEFFICACY AND RESIDUAL ACTIVITY OF FORMULATED PRODUCTS   
Before testing a whole trap in small-scale field studies, the efficacy of formulated 
products in traps (e.g. adulticide-treated netting, sticky surface inserts, attractant sachets, 
larvicides or other trap components) should be validated in controlled laboratory 
studies. Tests should measure the initial efficacy against laboratory-reared, susceptible 
mosquito populations of the targeted physiological stage (e.g. gravid females, host-
seeking females, larvae) and verify the proposed duration of efficacy of the products. 
For adulticide-treated trap components, methods can be adapted from cone bioassays 
(12, section 2.4.2). Formulated larvicides and insect growth regulators should be in 
accordance with laboratory methods described in the WHO guidelines for testing 
mosquito larvicides (13).
Procedures for testing attractant formulations, autodisseminants and sticky surfaces may 
require additional development and validation of published bioassays (e.g. 16–19). 
 
3.5 STATISTICAL METHODS AND DATA ANALYSIS   
An appropriate estimate of centrality (mean, 95% confidence interval or median, 
interquartile range) are calculated and reported for the outcomes. The activity of the 
test compound (e.g. adulticide, larvicide) against a particular vector strain can then be 
compared with values for other compounds.
3.5.1 ADULTICIDES, LARVICIDES, INSECTICIDE GROWTH REGULATORS, 
ATTRACTANTS
The relation between dose and mortality can be analysed by log–dose probit regression 
with relevant statistical software packages to estimate LC50, LC90 (or AC50, AC90) and 
95% confidence intervals.
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For insect growth regulators, total or mean emergence inhibition (EI) can be calculated 
from the number of larvae exposed and the overall emergence of adults. EI is calculated 
from: 
EI (%) = 100 − (T × 100)
                     (1/C)
where T = percentage survival or emergence in treated batches and C = percentage 
survival or emergence in the control.
3.5.2 REPELLENT AND EXCITO-REPELLENT ACTIVITY 
The relation between dose and percentage repellent and take-off due to irritability 
(excito-repellency) is analysed by log–dose probit regression.
3.5.3 DIAGNOSTIC CONCENTRATION 
The diagnostic or discriminating concentration is determined from the dose–response 
regression lines obtained by testing a technical material in a susceptible vector species. 
The diagnostic concentration is double that of the estimated LC99.9 estimated by probit. 
3.5.4 CROSS-RESISTANCE  
The LC50 value for susceptible mosquito strain is compared with those for several resistant 
strains to estimate the existence and level of cross-resistance (resistance ratio of 50% or 
95%) of the new candidate insecticide (20). 
 
3.6 INDICATORS FOR LABORATORY STUDIES   
The values listed below should be reported where appropriate from laboratory tests.
For new AI molecules for use in vector traps:
• intrinsic activity: LC50 and LC90 (both adulticides and larvicides); EI50 and EI90 
(insect growth regulators); AC50 and AC90 (attractants);
• excito-repellency: FT50 and FT90;
• transfer of autodisseminant: LC50 or LC90 or EI50 or EI90 of larvae exposed via 
transfer of the autodisseminant; 
• discriminating concentration of AI; and
• cross-resistance to insecticides in unrelated classes. 
For all formulated components for vector traps:
• bioefficacy of formulation: % mortality, EI or attraction of the target mosquito in 
the laboratory and the number of days the effect is maintained, according to 
product claims.
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4.   SMALL-SCALE FIELD TESTING (CONTAINED AND OPEN-FIELD 
TRIALS)
Small-scale, controlled evaluations of whole traps are performed with target mosquitos 
under contained field conditions and in small open field studies. Data collected in this 
phase are used to validate the claims of the manufacturer regarding efficacy and use, 
and to plan the next phase of testing in large-scale efficacy trials. The aims of small-scale 
studies are to determine the efficacy and duration of the effect of the whole trap against 
target vectors under controlled conditions and the effective trap application density (i.e. 
number of traps per unit area).
4.1  GENERAL CONSIDERATIONS FOR TESTING 
4.1.1 TEST SET-UP FOR SMALL-SCALE TRIALS 
Traps can be tested in large-cage or semi-field systems (contained trials) to simulate 
indoor or outdoor use conditions or in small-scale open field trials, depending on the 
end-point. Contained trials have the advantage of involving laboratory-reared mosquitos 
(reference or F1 of field-collected mosquitos) that are pathogen-free and of known age 
and physiological condition (e.g. gravid). Tests of oviposition traps in large cage and 
semi-field system experiments have shown good correlation with data from field tests; 
however, some end-points, such as effective trap density, can be measured only in 
open-field studies (Table 2). To estimate the duration of trap activity, traps are exposed 
to conditions of natural use (e.g. temperature, sunlight) and retested in contained trials or 
small-scale open field trials at set times after first use to measure their efficacy over time.
• Large-cage trials in laboratory enclosures: trials conducted in screened 
enclosures or free-flight rooms in a controlled laboratory environment with set 
temperature, light, humidity and air movement (21–23). 
• Semi-field trials in natural ecosystems: trials conducted in screened enclosures 
in the natural ecosystem of the target disease vector, in local conditions of 
ambient temperature, light, humidity and air movement. The environment should 
emulate the natural habitats of the target vectors (e.g. with endemic plants and 
vegetation, artificial containers) (24–25).
• Small-scale open-field trials: trials conducted in local settings at limited scale, 
e.g. a single village. They allow collection of data on end-points that may not 
be feasible in enclosed studies, such as effective trap density. Small-scale field 
trials should be conducted in settings that represent the environments in which 
traps are to be deployed (e.g. back yards, in and around houses) and where 
the target vector is endemic. 
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Table 2. Small-scale contained and open-field studies on vector traps
End-point Evaluation Trap type Indicator
Trap efficacy
Large cage, semi-
field
Capture–kill / 
capture–release
Immediate and delayed mortality (adults and/
or larvae) or EI 
Capture–kill / 
capture–release 
Trap oviposition rates (number of eggs per 
trap)
Capture–release Adult EI from secondary containers 
(dissemination)
Effective trap 
duration
Large cage, semi-
field and open field
Capture–kill / 
capture–release 
Number of days or weeks for which efficacy 
end-points meet product claims
Effective trap 
density
Open field Capture–kill / 
capture–release 
Optimal number of traps per unit area 
EI, emergence inhibition
4.1.2 MOSQUITOS AND COLLECTION METHODS 
For trials in large cages or semi-field systems, well-characterized laboratory-reared 
strains or F1 generation offspring of mosquitoes collected in the field should be used. 
Appropriate arthropod containment guidelines should be followed (26). For open-field 
trials, traps are assessed against local field populations of mosquitos at trial sites.
For contained trials, it is important to be consistent in the timing of mosquito release 
and data collection. Ideally, trials are conducted in the afternoon, with mosquitos 
released around 16:00 h and the traps monitored the following morning to minimize 
heat stress on the mosquitos. Running contained trials for longer should be justified in 
the trial protocol. For traps targeting gravid mosquitos, 6–8-day-old gravid females 
that took their first blood meal 2–4 days before the experiments and held with access 
to a sugar solution can be used. Tests of traps for host-seeking mosquitos can involve 
3–5-day-old nulliparous females that have been starved of sugar solution for 24 h. The 
conditions under which mosquitos are reared and held before use in experiments should 
be recorded, as this may influence the efficacy of traps (supplemental materials).
Trials in large cages or semi-field systems should aim to recapture recapture all mosquitos 
that were released so that the investigators can calculate the percentage mortality 
(including delayed mortality) and remove the remaining mosquitos via aspiration before 
further bioassays. Large cages or semi-field systems should be designed to allow 
collection of released mosquitos, through use of white netting, lowered ceilings, careful 
sealing of release chambers or placement of refuges such as black cloth-lined resting 
boxes in semi-field systems. It may also be necessary to use ant channels and daily 
cleaning to prevent scavenging of dead mosquitos. In all trials of this nature, there 
should be a wash-out period or other means of clearing all mosquitos between trials if 
they are not recovered through aspiration.
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Trained technicians skilled in the use of aspirators should perform collections, aiming to 
catch all mosquitos, knocked down or resting. The total number of recaptured mosquitos 
should be recorded to indicate if there is some unaccounted loss. Resting mosquitos can 
be captured with mechanical aspirators, sweep-nets or other methods and sampling 
repeated until, as far as possible, all the released mosquitos are recaptured.  
4.1.3 STUDY DESIGN CONSIDERATIONS
For longitudinal trap evaluations, it is important to sample systematically (e.g. weekly) 
throughout the test period. It is advisable to monitor the fitness (response to odour 
cues, egg laying or retention) of the released mosquitos. Wind speed and direction, 
temperature, relative humidity and precipitation should be recorded for each trial. Care 
should be taken to mount instruments out of direct sunlight, in the same location in 
each compartment for consistent comparisons of measurements. Between evaluations, 
products should be stored according to the label instructions or under environmental 
conditions similar to those used for evaluating the traps.
Experimental controls should be considered carefully. A standard negative control 
should be used in planned efficacy trials; for example, for gravid mosquitos, a black 
1-L container with 400 mL of deionized water is suggested. Alternatively, permutations 
of the trap with and without AIs can be used. Currently, there is no standardized active 
comparator for traps; however, commonly used surveillance traps for which published 
efficacy data are available, could be used as a reference to compare the performance 
of other traps. 
The number of replicates per product evaluated should be based on sample size 
estimates, which are required to ensure that a statistical evaluation has sufficient power 
(27). It is highly desirable that the study be fully randomized and that all field operatives 
be “blinded” to the allocation of treatments in order to avoid bias in the evaluation. If 
blinding is not possible because of the characteristics of the product (e.g. odour, colour), 
data should be blinded before analysis (28).
4.2  EVALUATION OF TRAP EFFICACY AND EFFECTIVE TRAP DURATION 
Trap efficacy is assessed for candidate traps in semi-field settings or large-cage or free-
flight rooms. The primary efficacy indicators are adult and/or larval mortality or EI, and 
trap oviposition. Where relevant, dissemination efficacy is indicated by mortality or EI 
from secondary oviposition containers. 
To measure adult and/or larval mortality (or EI), the candidate trap is tested against a 
control trap in a no-choice test (i.e. either the candidate test trap or the negative control 
is used in one of two experimental areas or chambers). Choice tests, in which mosquitos 
choose between a test trap and a control in the same experimental area, are used when 
measuring oviposition in traps and autodissemination efficacy. 
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Factors that could influence preference for a trap, such as location bias, should be 
controlled (e.g. in a Latin square design where possible (29)). Care should be taken 
to place the traps in the same way and out of direct sunlight so as not to alter their 
attractiveness or the efficacy of the AIs. If multiple traps are used in choice assays, trap 
distance – especially with attractants – should be considered, to account for interference 
among traps. Gravid test traps can be placed equidistantly at a minimum of 1 m apart, 
while host-seeking mosquito traps can be separated by longer distances (e.g. 10 m), 
depending on the product claims (30). Mosquitos can be released in the centre of 
the set-up so that they have an equal probability of encountering any of the traps (test 
or control). Traps can be labelled with unique identification numbers and assigned 
randomly to an experiment or sampling station with a random number generator. 
The number of replicates should be determined a priori by sample size calculation. 
For each replicate, at least 50 mosquitos (reared as described in section 4.1.1) 
are released into each large cage or semi-field compartment. For autodissemination 
trap trials, a maximum of 50 mosquitos should be used for each replicate. Each trial 
is terminated after the exposure time (usually the following morning or after 24 h). 
Standardized start and end times for trap operation should be used and recorded on 
data forms (see example in supplemental materials). At the end of the contained trial, 
the investigators should recapture all mosquitos, both in and outside traps, and record 
their status (alive, dead, gravid). A minimum recapture of 50% of released females is 
required for an assay to be valid. 
4.2.1 MORTALITY – ADULTS IN TRAPS
For capture–kill traps, such as sticky traps or traps that prevent mosquitos from exiting, 
adults retained in the traps should be identified and counted. For traps in which 
mosquitos are killed with an adulticide, recaptured mosquitos (in and outside the trap) 
may be held under optimum conditions, i.e. 27 ± 2 °C and 80 ± 20% relative humidity, 
for a standard period defined by the AI to measure mortality after the specified holding 
period, e.g. 24–72 h. The performance of the trap, as measured by the proportion of 
retained mosquitos (percentage of females trapped) or mortality (percentage of females 
dead per trap), is compared with that of a negative control, in which mortality should 
not exceed 20%. Traps designed to kill mosquitos by retention should be monitored for 
mosquito escape by appropriate methods, such as video recording or holding traps in 
small cages.
4.2.2 MORTALITY – LARVAE IN TRAPS
In traps intended to kill larval stages and prevent adult emergence, females are allowed 
to lay eggs, and the performance of the trap is measured by the number of eggs laid 
and the percentage hatching, larval mortality and/or EI. The maximum acceptable 
mortality in the control is 20%, and emergence in the control group should be 80% for 
the test to be valid. 
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4.2.3 ATTRACTION – OVIPOSITION
To measure attraction to ovipositing females and to rule out repellency, the performance of 
a trap can be measured in an oviposition choice test, in which an alternative oviposition 
container is provided, such as black, 1-L pots each holding a clear glass bowl with 400 
mL of water (6). The number of eggs laid in each oviposition site (candidate trap and 
secondary container) is used to calculate the percentage of eggs in the candidate trap 
and in the water-only controls.
If standardized recording of the first choice of oviposition location for Ae. aegypti is 
required, an additive (e.g. 0.07% Aquatain silicone oil) is applied to lower the surface 
tension of the water, which will cause female mosquitos to drown while ovipositing; 
however, the compound should be carefully selected to ensure that it does not deter 
ovipositing females. The performance of the trap is compared with that of the negative 
control and, if relevant, a standard (positive control). 
4.2.4 AUTODISSEMINATION
The efficacy of autodissemination traps and devices for killing mosquitos can be 
measured as described above. To avoid contamination, treatment and control traps 
should be tested in separate testing compartments (e.g. semi-field, large cage, free-flight 
room).
The efficacy in disseminating insecticide to secondary (or alternative) oviposition sites 
is measured in a choice test, in which two alternative oviposition sites (also called 
“secondary containers”) are provided. Secondary containers, such as black, 1-L 
pots each holding a clear glass bowl with 400 mL of water (6), can be placed at 
fixed locations a minimum of 1 m from the dissemination device, with two secondary 
containers per device.
To assess the efficacy of dissemination, 25 Ae. aegypti larvae (late L3 or early L4) and 
a larval food source are added to each secondary container. The following morning 
(or after a specified interval such as 24 h), the containers with larvae are removed and 
larval mortality and EI are monitored in the laboratory (13). The presence of eggs in all 
available oviposition sites is recorded.
Care should be taken when setting up an experiment to avoid contamination of 
secondary containers or control traps by handling, for instance by changing gloves 
between handling devices and decontamination procedures for moving devices 
between experimental compartments.
4.2.4 DURATION OF TRAP ACTIVITY
In order to evaluate the duration of efficacy, traps should be tested (mortality, capture, 
oviposition, dissemination efficiency) weekly to determine whether the efficacy targets 
are met, either for the duration specified on the product label or, if no claim has been 
made, the day on which the efficacy target falls below 50% of the initial level. Between 
tests, traps should be stored under normal conditions of temperature and sunlight. 
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4.3  EVALUATION OF TRAP DENSITY
The likelihood that an individual mosquito will come into contact with a vector trap 
depends on the local abundance of mosquitos, their habitat, the presence of competing 
aquatic sites and also the number of traps deployed in a given area. Trap density is 
an important consideration for efficient deployment, as a high density of traps might 
be expected to maximize the likelihood of mosquito capture, but reducing trap density 
would lower costs. The number of traps required in an area depends on the type of 
larval habitat, density of houses, housing characteristics, mosquito species and amount 
of open space available. Small-scale open-field trials are conducted to confirm the 
proposed trap density (number of traps per unit area) before large-scale field testing of 
traps.
The number of traps per defined area (a back-yard, for example) can be studied by 
comparing the trap capture rate with increasing trap densities (one, two, three or four 
traps per area). The optimal number of traps is reached when the number of mosquitos 
captured per trap reaches a plateau (Fig. 2). Trap density should be evaluated in 
both rainy and dry seasons, especially for devices that mimic oviposition sites, as they 
compete with larval development sites.
For autodissemination devices, the number of devices needed in a defined area can be 
Fig. 2. Measurement of trap density: (A) boxes represent defined areas with an increasing number of 
traps (circles); (B) in this example, the number of traps that capture mosquitos in each area plateaus 
at three traps (dashed vertical line), indicating the optimal number of traps to be used. This graph 
represents a predicted relationship assuming constant recruitment into mosquito population and 
density of competing attractants (e.g. host sources); the relationship between trap density and catch 
would also be influenced by these factors.
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estimated from the larval and pupal mortality and EI in sentinel aquatic sites (secondary 
containers) placed at known distances from the candidate autodissemination device, 
compared with similarly set-up in uncontaminated control test sites. As in contained 
testing assays (section 4.2.4), larval bowls from sentinel sites are taken back to the 
laboratory for bioassay.
4.4  STATISTICAL ANALYSIS
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The primary analysis should be a comparison of a candidate trap with a negative control. 
The statistical approach should include control for clustering and sources of variation in 
the experiment, such as replicate or location, in a mixed-effects or generalized linear 
model (i.e. distribution of families that are not necessarily normal).
 
Measures of centrality (e.g. mean, median, proportion) should be presented, with 95% 
confidence intervals or interquartile range, in addition to the results of statistical analysis, 
by giving the coefficient or odds ratio, value of the test statistic, associated P value and 
degrees of freedom. 
Many of the outcome variables measured in laboratory experiments are proportions 
(e.g. proportion of adults or larvae dead). These data can be analysed in a binomial 
model, but the denominator must be specified. Other variables measured are counts 
(e.g. number of eggs laid, number of captured mosquitos), which can be modelled with 
a Poisson or negative binomial distribution, depending on the degree of overdispersion. 
For slow-kill AIs, daily mortality rates can be assessed by Kaplan-Meier or Cox regression 
to determine whether the survival of the test groups differs significantly. 
Other appropriate tests include probit analysis to calculate the LC50 and LC90 if a dose–
response relation is required. Survival analysis (Cox proportional hazards, Kaplan–
Meier) may be appropriate to define the duration of effect.
4.5  SUMMARY OF EFFICACY INDICATORS FOR SMALL-SCALE AND SEMI-FIELD 
EVALUATIONS
The association between abundance and age structure of Aedes and disease transmission 
is not clearly defined and is likely to vary by ecological and epidemiological setting. 
Consequently, further evidence is required to set threshold values for the proportion of 
the Aedes population that a trap should remove in order to affect disease transmission
. 
Trap developers should seek to maximize efficacy in small-scale testing to ensure that 
the product has the highest possible mosquito catch rate in the field. For capture–
kill traps, a consistent rate of 70% mortality or capture for the claimed duration of 
efficacy is desirable before proceeding with large-scale field testing (section 5). For 
autodissemination devices, guidance will be revised as further data are generated.
 
A candidate trap is assessed against its efficacy in semi-field or large cage tests for the 
following variables: 
• adult mortality (immediate or delayed);
• larval mortality or EI;
• attraction-oviposition: trap oviposition rates (eggs in trap relative to control); 
• auto-dissemination: percentage adult EI from secondary containers; 
• duration of activity: number of days or weeks for which efficacy end-points 
meet product claims; and
• density of application: optimal number of traps per unit area. 
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5. LARGE-SCALE ENTOMOLOGICAL FIELD TRIALS OF VECTOR TRAPS 
Candidate vector traps that are efficacious in small-scale field trials should be validated 
in large-scale entomological field trials against natural Aedes spp. populations. These 
trials are intended to demonstrate whether use of the traps over an area can control 
local populations of Aedes spp. and/or change the age composition of adult female 
mosquitos. The experimental design must be statistically robust and have the power to 
demonstrate a specified reduction or difference in key parameters between treatment 
and control clusters. The tests should also indicate the physical durability and attrition of 
traps, user acceptance and effects on non-target organisms.
Details of methods for planning and conducting entomological trials are beyond the 
scope of this document, and the WHO manual on study design of field trials for vector 
control interventions (28), other resources (e.g. 31, 32) and a specialist in trial design 
and implementation for vector control should be consulted.
The objectives of such tests are to: 
• confirm the efficacy and duration of the effect of traps to reduce vector 
populations and/or alter population structure under field conditions at the 
defined trap density;
• assess the physical durability and attrition of traps in field conditions;
• observe and record the ease of application, handling and perceived adverse 
effects during product application and use; 
• for traps that include an insecticide component, determine insecticide 
resistance before and after the trial; and
• observe and record the effects on non-target organisms, including pests (e.g. 
Culex mosquitos) and beneficial insects (e.g. bees).
The design of large-scale entomological field trials must be robust and preferably be a 
cluster randomized trial that meets the criteria of replication, randomized trap allocation 
and adequate sample size. Vector traps in the treatment clusters are distributed at the 
intended density, coverage (i.e. number and placement of traps per unit area) and 
position inside and/or outside houses. Efficacy is assessed by comparing differences 
in vector population density and age structure (including sex ratio and parity) in the 
treatment and control (no traps) arms of the trial. Tests will also demonstrate the physical 
durability and attrition rates of traps, acceptability by users and effects on non-target 
organisms.
5.1. GENERAL CONSIDERATIONS FOR TESTING
The entomological outcomes of field trials on vector control interventions are specific 
for the setting in which the trial was conducted. Full assessment of the efficacy of 
candidate traps might require testing in several ecological settings and in different 
seasons, depending on the product claims. The area and location of trial sites should 
be representative of the target species’ habitat and the expected conditions of human 
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exposure. Generally, at least two well-conducted large-scale field trials are required for 
a WHO policy recommendation.1  
The WHO Vector Control Advisory Group recommends that first-in-class vector traps 
intended for public health initiatives be tested in trials that include epidemiological 
end-points (section 6), in addition to field trials with entomological end-points described 
here. Next-in-class traps do not need to show data on epidemiological efficacy and can 
be assessed from entomological data alone.
5.2. ETHICAL CONSIDERATIONS AND COMMUNITY SENSITIZATION 
Ethical approval should be received from the appropriate ethical committees before any 
trial procedures are started. The design of the study, participant information sheets and 
consent forms should undergo ethical review. Key considerations include: increased 
exposure to vector-borne diseases from additional aquatic sites or diversion of vectors, 
potential adverse effects associated with human exposure to the traps (as described by 
the manufacturer; see section 6) and effects on non-target organisms such as pollinators.
Human use protocols should clearly describe the potential risks associated with use 
of and exposure to the traps and strategies to mitigate such risks. Examples include: 
instructions for trap monitoring by project personnel and appropriate disposal (e.g. on 
completion of the study) to ensure that traps do not become larval habitats; exclusion 
criteria for households that cannot provide access for trap monitoring; and provision of 
clear descriptions of potential health risks to study participants when obtaining consent, 
including the contact details of study personnel and instructions for participants if they 
experience any physical symptoms associated with exposure to the traps. Households 
must be informed about the procedures and the frequency of monitoring visits associated 
with their participation in the trial.
Engagement strategies should include working with community leaders and members to 
inform them about the trial objectives. Informed consent must be obtained from individual 
households and/or the communities when appropriate. If trials are conducted in areas 
with possible virus transmission, control and treatment sites should continue to receive 
vector control according to the standard of care, including emergency control (e.g. 
space spraying) interventions. Coordination with local health authorities to keep the 
lines of communication open can mitigate the impact of these activities on trial results to 
ensure that all activities are properly documented and that all study clusters receive any 
emergency control measures equally.
Risk assessments that take into account the type of device, the attractant, the insecticide 
used and the environment in which the trap will be set may be required before testing, 
according to the protocols of the testing institutions. If during the field tests evidence 
arises that other insects (e.g. honey bees) are being collected or their populations 
reduced, further studies may be required to measure the impact.
1. Applicants are strongly encouraged to contact VCAG (vcag@who.int) to ensure that the appropriate 
procedures for generating evidence for public health are followed and to consult the latest guidance 
on its website and that of the WHO prequalification team for vector control products.
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5.3. STUDY DESIGN
WHO guidance on the design of phase 3 vector control field trials (28) should be 
referred to for additional guidance.
5.3.1 SAMPLE SIZE 
Before a trial begins, the necessary sample size should be estimated to ensure that 
the trial has enough power to quantify the effectiveness of vector traps against the 
entomological indicators of interest (33, 34). Local heterogeneity in Aedes numbers may 
influence the sample size and number of replicates.
5.3.2 DURATION OF TRIAL
Entomological field trials should be conducted over a minimum of a full transmission 
season, as trap performance is likely to depend on mosquito density and environmental 
conditions. Baseline characterization of local field sites is recommended; the data 
collected can be used for stratification and allocation of treatment and control clusters. 
For more details of study designs that require baseline data collection, see Wilson et al. 
(31). The benefits of planning longer trials should be considered, to account for the risk 
that atypical meteorological events (e.g. hurricanes), political or civil unrest or disease 
outbreaks (Aedes-borne or other infections) will confound or disrupt the trial. For first-in-
class products, where both entomological and epidemiological field trials are planned, 
VCAG recommends a 2-year trial duration, excluding baseline data collection, to 
generate data on the consistent entomological and epidemiological outcomes across 
consecutive high and low transmission seasons. 
5.3.3 STUDY AREAS
Study sites should be carefully selected to ensure that treated areas and controls are 
independent but comparable (e.g. in terms of ecology, housing type, predominant 
larval habitats and meteorological conditions). Clusters should be of similar sizes, with 
a minimum size equal to the flight range of Aedes spp. (150–200 m radius, e.g. a 
few blocks in urban sites and a single village in rural sites). Clusters should be spatially 
separated and not contiguous or adjacent. A separation of two to three times the flight 
range of Aedes spp. is ideal (300–600 m).
If isolated areas cannot be used for testing, traps can be deployed over a sufficiently 
large experimental area so that entomological assessment can be restricted to a central 
zone where the impact of treatment will be greatest. Mosquito density just outside the 
experimental area can then be measured and compared with that in the centre of the 
treated area.
The environmental conditions of temperature, humidity, rainfall and wind speed should 
be monitored and reported during evaluations for multivariate analyses and to quantify 
trends. Ideally, environmental conditions should be monitored at several points in the trial 
site. If this is not possible, data may be collected from weather stations in the study area. 
If the device being tested includes insecticides, the insecticide resistance profile of the 
target species in the testing area should be considered (15).
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5.3.4 PRE-INTERVENTION SITE CHARACTERIZATION 
As trials must have comparable treatment and control areas, preliminary characterization 
of the areas is essential. The length of the survey will depend on the study design. 
Baseline surveys are conducted to characterize parameters such as vector abundance 
(section 5.3.6), insecticide resistance and housing and other relevant characteristics 
to control for underlying sources of variation in the analysis or stratify allocation on 
variables with wide variation among clusters. For designs that compare study areas 
before and after trap deployment, the pre-intervention survey should be long enough to 
capture temporal variation in the study area.
5.3.5 TRAP PLACEMENT 
Trap density (per area or dwelling), coverage (percentage of area or dwellings with 
traps) and placement (preferred locations) are decided on the basis of manufacturers’ 
recommendations and the evidence provided by the small-scale trials. The number of 
traps required per study area in each trial depends on the type of trap, the size of 
the trial area, the estimated area covered by traps and the estimated adult mosquito 
population density before trapping. At a minimum, an adequate trial should achieve 
80% of the planned coverage (i.e. the predetermined number of traps required) in each 
study area; any shortfall in coverage should be recorded and reported. If the study 
design specifies that trap placement be accompanied by larval source reduction (e.g. 
removal of tyres and other secondary containers), similar source reduction should be 
undertaken in the control arms of the trial.
5.3.6 ADVERSE EFFECTS (SEE ALSO SECTION 6)
Adverse effects and events due to use of the trap product, general acceptance by local 
inhabitants and attrition (missing or destroyed traps) in the trial area should be observed 
and recorded, such as for instance records of people who did not accept to participate 
or dropped out and those who were retained (35). A GIS database may be useful for 
monitoring traps and trap attrition.
5.3.7 SAMPLING AND MONITORING
Ideally, more than one monitoring method should be used for assessing effects on 
Aedes populations or mosquito survival. Sampling schemes (number of days sampled 
per week) should be standardized for all study areas. For interventions targeting Ae. 
aegypti, sampling should be conducted in or around households.  Ae. albopictus is 
found in a wider range of habitats both near and far from human population centres 
(urban, rural and forested). Methods for sampling should be evaluated under local 
conditions before use and with consideration of the local ecology of the target vector.
If traps are used for monitoring in field trials, these should be placed at a distance far 
enough from the intervention trap that there is no competition between the two (e.g. not 
in the same household or room).
The recommended sampling methods are adult aspiration for Ae. aegypti (e.g. CDC 
Backpack, Prokopack) and traps for Aedes surveillance (e.g. BG Sentinel traps, 
autocidal gravid ovitrap, gravid Aedes trap, infusion-baited ovitraps) (36) (Fig. 3). 
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Larval or pupal surveys provide valuable supplementary information on Aedes ecology 
in study areas, but indices for such immature stages should be considered secondary 
measures. The presence of eggs in ovitraps can indicate the presence or absence 
of Aedes spp. and is used in many programmes; however, because the density of 
both larvae and eggs in ovitraps depends on the availability of containers and is not 
necessarily directly related to changes in adult density, this measure is not recommended 
for assessing the effect of vector traps on populations. 
Human landing collection of Aedes mosquitoes is not recommended where there is the 
risk of exposure of field collectors to arbovirus and the lack of prophylaxis for Aedes-
borne diseases. Some researchers have used double nets or electrified nets to collect 
Aedes mosquitos in the field, thus preventing human baits from being bitten (41,42). 
Sweep net collections have been used for collecting adult Ae. albopictus (43).
Methods for surveillance of Aedes mosquitos have been described comprehensively 
elsewhere (4, 36, 44), including the use of infusion-baited ovitraps. 
5.4. MEASURING EFFICACY OF TRAPS AGAINST ENTOMOLOGICAL END-
POINTS
The objective of entomological evaluations is to determine whether the adult female Aedes 
population or mosquito survival is reduced significantly by the vector trap intervention. 
To determine the effect of traps on the target vector population, adult densities and age 
structure should be evaluated by collecting samples in treatment and control areas by 
the same standardized sampling scheme used for baseline characterization of the site. 
Sampling should be frequent enough to account for temporal and spatial variation in 
the mosquito population throughout the trial. For guidance, sampling intervals of 1–3 
weeks should be used.
Fig. 3. Common sampling devices for Aedes spp. mosquitos. (trap images adapted from reference 36)
  BG-Sentinel 2  Autocidal gravid ovitrap  Gravid Aedes trap  Prokopack  
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5.4.1 ASSESSMENT OF ADULT POPULATION DENSITY
Adult mosquito densities in and around houses in treatment and control areas can 
be monitored at fixed trapping points (in adult traps) or in house-to-house surveys (by 
aspiration). House-to-house surveys cover more houses per unit time and ensure better 
spatial coverage than fixed traps, but they are labour-intensive and depend strongly 
on the skill and diligence of the operator. Fixed trap methods better capture short-term 
temporal variation.
Sampling procedures should be standardized as far as possible to maximize consistency 
in the results. Detailed procedures for household surveys with aspirators are provided 
in the WHO guidelines on evaluation of space sprays (45). The aim of the procedures 
is to sample the adult vector population in the study areas reliably, as expressed by the 
average number of mosquitos per room, per house or per other defined unit sampling 
point. 
5.4.2  ASSESSMENT OF MOSQUITO POPULATION STRUCTURE AND PHYSIOLOGY
The age structure of the mosquito population in the field can be estimated from the 
frequency of nulliparous and parous mosquitos. The proportion of parous females is an 
indirect measure of the probability of daily survival of mosquitos in the population. Parity 
is a useful indicator in mosquito populations that are stable over time, as demonstrated 
by surveillance in the study area, for example during site characterization before the 
intervention.
5.4.3  AUTODISSEMINATION EFFICACY
While the aim of large-scale entomological field trials is to detect entomological 
effects on the population due to the presence of vector traps, for traps that function by 
autodissemination, it may also be useful to monitor the efficacy of autodissemination over 
time. Autodissemination monitoring ovicups (46) or larval bioassays in water sampled 
from natural aquatic habitats (i.e. water bodies with Aedes larvae) can be used to measure 
autodissemination efficacy. Laboratory-reared Aedes larvae added to these samples and 
Aedes larvae collected from natural sites are monitored for emergence inhibition. For 
ovicup monitoring, a trap:ovicup ratio of no more than 1:5 is recommended to avoid 
an effect of ovicups on the overall mosquito population. Autodissemination efficacy may 
increase with time due accumulation of the autodisseminant (e.g. pyriproxifen) from 
multiple visits of mosquitos to the oviposition site or ovicup. 
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5.5. PHYSICAL INTEGRITY AND DURATION OF EFFECT
Most traps require periodic servicing or maintenance. Trap durability and efficacy 
should be assessed during the servicing interval (i.e. the time in days or months for 
which products are effective without servicing), and a longer-term assessment should 
be done to determine trap integrity and retention or loss and to confirm the duration 
of trap efficacy. The duration of each study should be appropriate for validating the 
manufacturers’ claims. During servicing, physical integrity and trap presence should be 
recorded, and quality assurance assays can be conducted on certain components of the 
traps. Alternatively, assessments can be made of manufacturers’ claim by simple random 
sampling of traps in the study area.
A standard sampling questionnaire should be used to collect data on the integrity, 
durability and attrition of traps. Mobile devices and GIS databases may be helpful for 
data collection and tracking and should be explored. The aspects listed below should 
be investigated.
• Physical integrity: A standardized form should be prepared for recording 
the general condition of the trap, including (where relevant) condition of 
insecticide components or adhesive strips (e.g. presence, whether torn or 
have holes), water levels, presence of larvicide or attractant. 
• Trap functionality: presence of adult and immature mosquitos and other 
insects.
• Quality assurance of trap components (see section 3.5): bioassays with 
insecticide-treated materials in traps, assessment of adhesives and evaluation 
of larvicidal activity.
• Trap attrition: whether traps have been lost or moved, whether residents have 
washed or modified the traps against study instructions.
• Household retention: withdrawals and coverage rates.
5.6. OBSERVED NON-TARGET EFFECTS
Candidate traps tested under field conditions must be assessed for ecological and 
human toxicity before a field study is conducted. Detailed treatment and analysis of these 
data are beyond the scope of this document; however, during large-scale trials, when 
appropriate, qualitative observations should be recorded on non-target species that are 
protected or would affect allied species such as bees and other pollinators (47). For 
example, non-target organisms found in traps or any noticeable impact on cohabiting 
organisms found during larval sampling (e.g. fish, copepods, other mosquito larvae) 
could be noted. 
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5.7. EFFICACY INDICATORS FOR ENTOMOLOGICAL FIELD TRIALS
A candidate trap, with bait and/or insecticide, is tested for efficacy in large-scale 
entomological trials against the following primary criteria: 
• local adult Aedes mosquito population density: significant difference in 
mosquito population density between treated and control areas;
• local adult Aedes mosquito population structure: significant decrease in the 
proportion of older female (parous) mosquitos. 
The following secondary indicators support efficacy assessments, and, when possible, 
the results should be reported. 
• sex ratio shift: a significant increase in the proportion of males in the treated 
area;
• oviposition rates: significant decrease in mean egg catch in the treated area;
• physiological status: significant decrease in the number of blood-fed females 
collected in the treated area; and
• infection rate: proportion of vectors infected (see section 6.3).
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6. COMMUNITY TRIALS OF IMPACT ON DISEASE
The public health effect of first-in-class vector traps against natural vector populations is 
assessed in community trials of the epidemiological impact on the incidence of Aedes-
borne virus (ABV) or Aedes-borne disease in study clusters with and without traps. 
Before traps can be recommended for public health programmes, evidence is required 
to support the principle that a vector trap strategy can reduce infection and/or disease. 
To that end, the Vector Control Advisory Group recommends that at least two well-
implemented, randomized, controlled trials be conducted of epidemiological outcomes 
in different eco-epidemiological settings for a full assessment of the public health value 
(i.e. reduction of infection and/or disease) of this intervention strategy (48). The duration 
of epidemiological assessment, excluding the baseline period, should cover at least 2 
years, to account for inter-annual variation in transmission. Individual next-in-line traps 
may not require such evidence, and applicants are strongly encouraged to contact the 
relevant WHO programmes (i.e. VCAG and PQT-VC) to ensure that the appropriate 
evidence is generated. 
Large-scale entomological field trials are described in the previous section. As detailed 
methods for planning and conducting epidemiological trials are beyond the scope 
of this document, the WHO manual on study design of field trials for vector control 
interventions (28), other resources (e.g. 31, 32) and a specialist in epidemiological trial 
design and implementation for vector control should be consulted.
Study designs are affected by conditions that are impossible to control, including 
household access and coverage, heterogeneous housing, movement of people, security 
issues and other public health programme activities, as well as unpredictable virus 
transmission dynamics. Accurate evaluation of interventions requires a robust study 
design. 
The objectives of a community trial are to:
• demonstrate the protective efficacy of traps for ABV transmission and/or Aedes-
borne disease incidence; 
• monitor severe and adverse events in the human population; and
• observe and record acceptability, coverage and maintenance during product 
application and use (the trap itself and the bait and/or insecticide), ease of 
application and handling, associated costs and any consequences associated 
with maintenance failure (trap loss and conversion into a larval habitat). 
In this section, we describe measurement of virus transmission, disease and related 
proxies, ethical considerations, human safety, blinding and trap effectiveness.
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6.1. MEASURING TRAP EFFICACY AGAINST EPIDEMIOLOGICAL END-POINTS
The primary epidemiological end-point is demonstration of the protective efficacy of the 
trap intervention. As an expected rate of protective efficacy is required for calculating 
sample size, a minimum of 30% is recommended.1 Entomological end-points should be 
consistent with the mode of action of the traps (see section 5). Defining strategies for 
monitoring virus transmission or disease in human populations is particularly challenging 
for Aedes-borne diseases. In these guidelines, we focus on diseases caused by dengue, 
Zika and chikungunya viruses. Dengue and Zika viruses are in the family Flaviviridae, 
whereas chikungunya virus is in the family Alphaviridae.
During the first 5 days of acute infection, virus can be detected by cell culture or 
polymerase chain reaction (PCR) of key RNA sequences. Effective disease surveillance 
systems and confirmatory laboratory diagnostic capacity are required to identify and 
test potentially infected individuals. When possible, several strategies should be used to 
measure infection (section 6.1.2) and/or disease (section 6.1.3) in community-based 
trials. All residents in the study area can be monitored for disease. For infection, a subset 
of residents most likely to be susceptible (e.g. children) is identified during the baseline 
screening study. Blood samples from these individuals are tested at regular intervals to 
monitor seroincidence.
Monitoring multiple epidemiological parameters will increase the probability of 
detecting PE if an intervention is effective, but monitoring both disease and infection is 
not a requirement and may not be feasible or appropriate in certain locations. PE can 
be sufficiently demonstrated with a single epidemiological endpoint.
6.1.1  BASELINE AND SCREENING STUDIES
As Aedes-borne viruses cause “sterilizing immunity” to the infecting virus serotype, the 
age-specific seroprevalence of arbovirus serotypes in the study population should be 
known to understand heterogeneity among clusters and to stratify the allocation of traps. 
Residents in the study cluster(s) should be screened to determine prior ABV exposure, 
and only those showing negative or monotypic ABV response should be included as 
participants in the sero-incidence studies (section 6.1.2). Because of significant cross-
reactivity in diagnostic tests between dengue serotypes and Zika virus infections, 
inclusion of participants with a multi-typic response is not recommended. 
The serological status of study residents is used to identify a longitudinal cohort (see 
section 6.1.2) and to characterize the susceptibility of the human population in each 
study cluster to ABV infection. This information can be used to stratify clusters before trap 
allocation (e.g. clusters can be stratified into high, medium and low seroprevalence 
groups), and allocation to treatment and control be balanced within each stratum. 
Serology is the method used to detect ABV infection after the acute phase of infection is 
over. Plaque reduction neutralization or microneutralization assays should be performed, 
1. The value of 30% protective efficacy was intended as a conservative, practically achievable rate 
of protection, as recommended during expert consultation and a review of similar efficacy trials of 
targeted interventions against Aedes.
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when possible, to determine serotype specificity. Alternatively, an immunoglobulin G 
enzyme-linked immunosorbent assay (IgG ELISA) can be used to distinguish between 
naive and previously exposed individuals, although this assay is not serotype-specific. 
Fig. 4 summarizes the timelines for antibody responses and detection methods after 
dengue infection. The WHO guidelines on dengue diagnosis, treatment, prevention 
and control (36) should be consulted for details and resources. 
6.1.2  SEROINCIDENCE STUDIES
A subset of the population in the study clusters should be recruited for longitudinal blood 
sampling. Blood samples collected at 6–12-month intervals from the same individuals 
are tested for virus in plaque reduction neutralization or microneutralization assays, as 
described above for baseline surveys. Ideally, the cohort members should have had no 
prior ABV infection, exception for dengue virus, when inclusion of individuals who have 
been exposed to a single virus serotype would be appropriate. Studies suggest that in 
most dengue-endemic regions > 90% of adults have had at least one dengue infection. 
Therefore, paediatric cohorts are recommended, as the risk of infection increases with 
time. 
Fig. 4. Approximate timelines of primary and secondary dengue virus infections and methods that can 
be used to detect infection 
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When an individual has antibody titres above the threshold level after a previously 
negative blood sample, he or she is assumed to have developed an infection during the 
time between the two samples. Individuals who show no change in antibody titres are 
assumed not to have seroconverted. Seroincidence rates can be calculated by cluster 
and time interval from all individuals who provide paired blood samples:
Seroincidence rate = number of seroconversions / sum person-time.
Alternatives to this approach include IgG ELISA or haemagglutination inhibition assays 
on blood samples taken at 3–6-month intervals to identify seroconversion. IgG ELISA 
of saliva samples has been used as a proxy to identify dengue virus transmission, but 
positive samples do not necessarily represent new infections (49).
6.1.3  DISEASE SURVEILLANCE
A second strategy for measuring public health impact is quantification of cases of Aedes-
borne disease within study clusters. Study participants can be instructed to present to 
local health facilities when they have symptoms, or an active disease surveillance system 
can be set up. Historically, fever has been a clear trigger for either presenting to a health 
facility or as a key criterion for identifying individuals to be screened for ABV. As many 
cases of Zika virus disease do not present with fever, study participants can be told to 
watch for rash and/or fever accompanied by joint pain and/or red eyes (50). It is 
critical that the surveillance protocol and case inclusion criteria be consistent for all study 
clusters throughout the study.
Blood samples from both acute and convalescent cases should be obtained for 
laboratory diagnosis. Samples taken during the first 5 days of illness should be tested 
by PCR or nonstructural protein 1 (NS1) testing. When individuals present with clinical 
symptoms but test negative by PCR, a further blood sample should be taken 14–21 days 
later to test for virus-specific IgM or IgG antibodies (Fig. 4). 
In all trials, disease surveillance protocols must be consistent and the population 
participating in surveillance be well characterized. The most commonly used disease 
surveillance strategies are listed below.
 
Passive surveillance in health facilities or by study personnel
Study participants can be given clear instructions to notify study personnel or to present 
to a designated local study clinic if they have fever or other specific symptoms. Usually, 
they are given a card that identifies them as study participants and provides contact 
information. This strategy works well if access to facilities or study personnel is readily 
available. As the method relies on the initiative of study participants, it can be improved 
by periodic phone calls or reminders. Health-seeking behaviour varies, especially by 
age. Passive case-finding should be considered a complementary outcome, and active 
surveillance is preferred to avoid treatment-seeking bias.
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Surveillance in schools or workplaces
Absence from school or work has been used as a trigger for visiting study participants 
and obtaining samples for diagnosis if the absence is due to illness. Although this 
system may be effective for epidemiological studies, it is not a recommended strategy 
unless the experimental units are schools or workplaces. This type of surveillance may 
reveal cases, but it greatly restricts the size of the surveillance cohort. For community 
interventions, surveillance at the household level conducted by active house visits is 
preferred.
Active house visits 
Households in the study clusters may be visited once to three times a week to ask whether 
individuals have fever or other symptoms. Although this system is labour-intensive, it is 
the most sensitive approach for identifying potential cases.  Furthermore, individuals 
who are ill who do not agree to provide samples can be counted to identify potential 
participation bias in clusters.
Household census (denominator)
Calculation of seroincidence rates requires reliable, precise estimates of the number 
of individuals under surveillance. This requires household censuses and monitoring 
of residents’ movements in and outside households to document their presence and 
absence in the study area. Census information must therefore be updated periodically.
Time in house (exposure)
As traps are deployed at cluster level, additional studies are required to determine the 
proportion of time individuals in the population under surveillance are exposed to the 
vector control intervention at both household and cluster level. This information can be 
collected through interviews or methods such as GPS tracking. Both seroconversion and 
seroincidence calculations will have to be adjusted to person–time data to account for 
time not exposed to the intervention.
6.1.4  CROSS-SECTIONAL SURVEYS
During periods of very high transmission, a series of standardized cross-sectional surveys 
across clusters could be used to identify infected people in order to determine the public 
health impact of an intervention. Although this strategy is not recommended as the 
primary or only epidemiological method, it would be appropriate after the introduction 
of a novel virus or serotype into a study area (for example, during periods of epidemic 
transmission). To increase the probability of detecting a significant public health impact, 
a protocol including sample size calculations could be prepared in advance for use in 
the case of an outbreak. If high rates of ABV infection are documented, the duration 
of the trial could be shortened. A random selection of individuals in each cluster under 
surveillance would provide blood samples each month to be tested for evidence of 
acute infection (PCR, IgM and NS1).
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6.1.5  CHANGES IN MOSQUITO INFECTION RATE 
As part of entomological monitoring in a trial, adult female mosquitos may be tested 
for ABV by PCR or NS1. Mosquitos that have had recent blood meals should be tested 
separately from those without evidence of a recent feeding and from gravid mosquitos. 
All species of mosquito, including abundant Culex mosquitos, with recent blood meals 
can be tested for ABV, as these will test positive if they have recently fed on an infected 
person even if they are not vectors of the disease. Positivity in gravid and non-gravid 
Ae. aegypti (or other known Aedes) females is used to estimate the number of infectious 
mosquitos in each cluster. The mosquito infection rate is potentially a proxy for human 
infection. At present this would be an appropriate secondary outcome, but it cannot 
substitute for seroconversion or disease incidence.
6.1.6  BLINDING 
To reduce potential study bias, blinding to the intervention is usually recommended in 
clinical trials. When traps are used, blinding of study participants and field staff may 
not be practical; however, measures should be in place to ensure blinding of laboratory 
data, both virological and entomological, as well as data management and analysis. 
A standard of care alternative, such as larviciding, is recommended for comparison in 
all study clusters, both intervention and control. Equal, standardized treatment must be 
used in all study clusters for disease surveillance. Mock trap devices (with no water, no 
insecticide, easy escape) could be used; however, this approach is limited because 
participants must have information on trap components and their risks before they 
provide informed consent.
Teams responsible for different components of the study (disease monitoring, 
entomological monitoring, trap deployment and maintenance, laboratory) should work 
independently to avoid unintentional bias. For example, different teams should be 
responsible for implementation and for evaluation. 
6.2. ETHICAL CONSIDERATIONS, STUDY REGISTRATION AND MONITORING
Full ethical considerations are not covered in this document, and appropriate sources 
and experts should be consulted during the planning of trials. Guidance on the ethical 
design and conduct of cluster randomized trials is provided in the Ottawa Statement 
(51).
6.2.1  STUDY REGISTRATION
It is strongly recommended that community trials (randomized controlled trials) be 
registered as clinical trials in an appropriate registry before they are initiated. This step 
has a number of important implications: (i) compliance with local regulatory institutions 
by passing all protocols through national institutional review boards responsible for 
clinical trials; (ii) a clear plan for allocation of the intervention, including a method for 
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generating an allocation sequence, a list of the factors used for stratification and a 
method for implementation; (iii) a clear statement of who will be blinded (participants, 
study personnel, data analysts) and how; (iv) data monitoring and audits; and (v) 
monitoring of safety and structures for implementation, e.g. a data safety monitoring 
board. In addition, it is best practice to have documented procedures (standard operating 
procedures) for all aspects of trial conduct and data collection, e.g. for procedures such 
as drawing blood, trap deployment, mosquito collection and data management. 
6.2.2  MONITORING OF ADVERSE EVENTS
Although most anticipated trap designs are not expected to be associated with more 
than minimal risk, many contain chemical insecticides or parts that could be ingested 
or cause allergic or physical reactions on physical contact. Severe adverse events must 
be distinguished from expected minor-to-moderate adverse events described in the 
manufacturer’s brochure.
Examples of severe adverse event include death or severe injury after choking on a 
trap component, asthma requiring hospitalization induced by exposure to a chemical 
component of a trap or serious injury due to tripping over a trap. The rules for reporting 
severe adverse events depend on the institutional review board or ethics committee; 
however, a severe adverse event that is likely or potentially to be attributable to the 
intervention must be reported within 24 h and be reported formally within 5 working 
days (these times might vary). Severe adverse events that are not likely to be associated 
with the intervention should also be reported to institutional review boards and to data 
and safety monitoring boards under their defined conditions (annually or quarterly). 
The events will be analysed by these independent boards for any unusual patterns or 
unexpected association with the intervention.
A critical component of a community trial is quantification of adverse effects of special 
interest. Examples include mild skin or eye irritation after contact with the trap, allergic 
reactions or increased symptoms of mild asthma. Unexpected adverse events, even if 
they are not severe, must be reported promptly. Clear reporting and recording protocols 
are required for complaints from participants about such events to study personnel. 
If possible, complaints should be followed up by study medical personnel for better 
characterization. Study databases should include tables for recording events linked to 
affected participants. As many such events are mild, participants may not report them 
to study personnel; therefore, at the time of consent, expected adverse events should 
be described and participants encouraged to report them to study personnel. Further, 
when participants withdraw from a study, they should be asked about the occurrence of 
adverse events and whether they were a factor in their decision to withdraw. Separate 
questionnaires or a complement to disease surveillance could also be used. In all cases, 
it is important not to introduce bias or potentially unblind studies.
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6.2.3  INDEPENDENT MONITORING
It is recommended that independent entities be engaged through a contract research 
organization to monitor trials, such as a data and safety monitoring board for adverse 
events and independent quality assurance.
6.3. TRAP MONITORING, MAINTENANCE, COVERAGE AND SCALE-UP
The objective of the community trials is to test traps under the most closely controlled 
conditions possible. This often requires that trap maintenance be managed by study 
personnel, which may not be feasible in national vector control programmes. We 
recommend, if possible, use of pilot studies to examine how the community or the 
programme staff will be involved in trap maintenance. 
6.3.1  TRAP MAINTENANCE 
Trap specifications must be clearly defined, including the requirements for their use 
(addition of water, baits) and frequency of maintenance (cleaning and/or recharge). 
Compliance with these specifications should be monitored and recorded, as should 
movement and alteration of traps and those that are no longer effective, for example 
traps that have been tipped over or emptied and then returned to their position without 
larvicide. 
6.3.2  TRAP COVERAGE 
Coverage must be monitored throughout the trial, including the proportion of lots 
(housing and other) with traps; the proportion of lots with traps in place, functioning as 
planned and cleaned or recharged successfully; and traps that have disappeared and 
households that withdraw from the study. A monitoring system should be in place that 
tracks individual traps.
Although the coverage required for a public health impact is unknown, it is recommended 
that studies maintain 80% of the planned coverage. For example, for area-wide 
protection, the aim would be to include at least 80% of the planned houses or properties 
in the study area. Importantly, for the households participating in disease monitoring, 
studies should demonstrate that traps were in place and properly maintained 80% of the 
time and that at least 80% of the households were retained for the duration of the study. 
It may be difficult to achieve this proportion in field trials. The total numbers of traps, 
participating households and properly maintained traps must be recorded throughout 
the study (Box 1). 
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Box 1. EXAMPLE OF CALCULATING AND MAINTAINING TRAP COVERAGE
Initial coverage
In a study with a lethal ovitrap that requires that the larvicide component be changed every month 
and an optimal density of three traps per property in a study cluster of 100 houses, the cluster 
should have 300 traps, with three on each property. After initial deployment, spatial coverage can 
be calculated from: 
number of houses with traps / number of houses in the cluster.
For example, if 80 of 100 household accepted traps, coverage would be 80%; alternatively, 240 
of 300 traps, would be 82% coverage.
Follow-up
Each household would be visited monthly for 1 year. For the 80 participating houses, the larvicide 
would have to be changed 960 times. As some people might not be at home, in this example there 
should be a minimum of 768 successful visits (768/960 = 80%). 
Some households withdraw or traps are lost. For example, if 10 household withdraw, the coverage 
rate would drop to 70%. Coverage should be monitored by cluster and at each appropriate 
monitoring visit.
Houses may have damaged traps. If 50/80 houses lose one of three traps, (30 x 3) + (50 x 2) 
= 190 traps would remain (63% coverage). Trap density during follow-up should therefore also be 
calculated. 
6.3.3  SCALING-UP TRAP INTERVENTIONS  
Extending the use of vector traps may require a wide array of measures that are not 
included in this document. One issue relevant to traps is ensuring distribution and 
maintenance. Distribution schemes should be tested in effectiveness trials, with coverage 
as the relevant end-point. Consideration should be given to trap maintenance (ideally 
by the community), monitoring and evaluation procedures and plans for disposing of 
used and unused traps. 
6.3.4  COMMUNITY PERCEPTIONS AND ACCEPTANCE
A social component to assess communities’ reaction to the intervention should be 
included. A variety of qualitative research techniques are available, such as focus group 
discussions and key informant interviews. Additionally, periodic quantitative surveys 
should be carried out of community perceptions about the acceptability and efficacy of 
the traps.
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SUPPLEMENTAL MATERIALS
S1. SAMPLE PROCEDURE FOR EVALUATING AUTODISSEMINATION AGENTS
Autodissemination is the ability of adult mosquitos to pick up a contaminant from treated 
solid surfaces and to retain and transfer it to aquatic habitats in sufficient quantities 
to contaminate the habitats, rendering them unproductive, either by killing larvae or 
preventing pupae from emerging to adults.
The aim of this assay is to establish the dose–response relation of the autodisseminant on 
the adult mosquitos to achieve 50% and 90% mortality of susceptible mosquito larvae 
that are exposed by transfer of the autodisseminant from the adult to the larval habitat. 
The protocols are adapted from Sihuincha et al. (1), Lwetoijera et al. (2) and WHO (3); 
however, further independent validation of this assay may be needed.
 
Mosquito species and test conditions
Tests should be conducted on well-characterized, strains of mosquito that are susceptible 
to all major insecticide classes with no detectable resistance mechanisms, reared 
according to standard institutional protocols (e.g. 27 °C ± 2 °C, 80% ± 10% relative 
humidity and photoperiod 12 h light:12 h dark). For autodissemination experiments, 
blood-fed and gravid mosquitos (e.g. 6–8-day-old females that took their first blood 
meal 2–4 days before the experiments) on sugar meals (e.g. 10% sucrose) should be 
used.
Methods
A modified bottle bioassay (4) is used for testing active ingredients (AIs) for 
autodissemination. In this assay, 1 mL of a solution of either the carrier or solvent alone 
(e.g. acetone) or of the desired concentration of insecticide in the same carrier or solvent 
is placed in a 250-mL glass bottle (e.g. Wheaton®). Dilutions of AIs should represent 
five to six test concentrations that cause 0–100% inhibition of emergence of larvae. A 
minimum of four replicates of each serial concentration and two control bottles (solvent 
only) should be prepared.
Groups of 5 female mosquitos are added to each bottle and exposed for 30 min and 
1 h. Control mosquitos are maintained in bottles containing only the solvent for 1 h. The 
bottles are turned every 15 min to maximize the chances that the mosquitos will pick up 
the candidate autodisseminant. 
After exposure, the mosquitos are removed from each bottle and transferred to screened 
cages with bioassay containers (3) containing 200 mL water and 25 late-stage L3 / 
early L4 Ae. aegypti larvae with a larval food source. The containers are lined with filter 
paper as a substrate for oviposition, and mosquitos provided with access to 10% sugar 
solution. After a specified time (e.g. 24 h), adult mosquitos are removed, and mortality 
and inhibition of larval emergence are monitored in standard larval bioassays (3).
If adult emergence in the controls is < 80%, the test should be discarded and repeated. 
If the percentage in controls is 80–95%, the data may be corrected with Abbott’s 
formula. Cumulative totals of dead larvae and pupae from each assay are pooled for 
dose–response analysis by probit analysis.
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S2. SAMPLE DATA REPORTING FORM FOR SMALL-SCALE TRIALS
Date/time start:___________ Temperature/relative humidity: ___________               Location: _____________
Time stop: ___________  Temperature/relative humidity: ___________
 
          
Test item:___________________ Control 1: _______________  Control (If positive standard used): ____________
          
Test system/strain: ______________  Mosquito age: ____________    Time blood-fed: ______________
Number replicates: _____       Mosquitos released/cage: 1________ 2________  3________  4________ 
 Trap location  
 Cage A B C D E F No. alive No. dead Total recovered
1 Treatment 
No. trapped/ No. eggs
2 Treatment 
No. trapped/ No. eggs
3 Treatment 
No. trapped/ No. eggs
4 Treatment 
No. trapped/ No. eggs
Specificities of attractant (if any): _________________________________________________________________
 
           
Collector(s): _________________________  Notes:      
 
           
Data recorded by: _________________________      
 
           
Control mortality: _________________________ Acceptable range is < 10% for adulticide   
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New tools to target and suppress Aedes populations are needed 
to protect people living in areas of risk for arboviral disease. The 
purpose of this document is to provide procedures and criteria for 
testing the efficacy of and evaluating vector traps for disease control. 
It includes the design of laboratory and small-scale field trials to 
assess the attraction and killing effects of vector traps and of large-
scale community trials to determine the efficacy of traps in reducing 
mosquito populations in the field and disease transmission. This 
document is intended to support product developers, programmes 
and testing institutions generate robust entomological evidence of the 
efficacy of vector traps for control and, for a first-in-class vector trap, 
evidence of the public health impact in reducing arboviral disease.
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